Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Radiopharm Theranostics's
Operating Income
for the
six
months ended in Jun. 2025 was $-9.66 Mil. Radiopharm Theranostics's Interest Expense for the
six
months ended in Jun. 2025 was $-0.04 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Radiopharm Theranostics's Interest Coverage or its related term are showing as below:
RADX's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 98.255 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Radiopharm Theranostics Interest Coverage Related Terms
Radiopharm Theranostics Interest Coverage Historical Data
* Premium members only.
The historical data trend for Radiopharm Theranostics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
RADX vs VRTX, REGN, MRNA: Interest Coverage Comparison
For the Biotechnology subindustry, Radiopharm Theranostics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Radiopharm Theranostics did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Radiopharm Theranostics (RADX) has a Interest Coverage of 0 (At Loss) as of Jun. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Radiopharm Theranostics and its competitors. According to the industry distribution chart, Radiopharm Theranostics ranks #999999 out of 368 companies in the Biotechnology industry.
Is Radiopharm Theranostics' Interest Coverage too high?
Radiopharm Theranostics' current Interest Coverage is 0 (At Loss). Based on the distribution chart, Radiopharm Theranostics ranks #999999 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Radiopharm Theranostics has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Radiopharm Theranostics' Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #999999 out of 368 companies for Interest Coverage. This places Radiopharm Theranostics in the lower half of its industry. The industry median Interest Coverage is 98.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 98.26, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Radiopharm Theranostics and its competitors. For the Biotechnology industry, the median Interest Coverage is 98.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Based on GuruFocus' analysis, Radiopharm Theranostics (RADX) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.34, compared to a current price of $2.08 — trading 11.1% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Radiopharm Theranostics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Radiopharm Theranostics (RADX), the current Interest Coverage is 0 (At Loss) as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Radiopharm Theranostics (RADX) Overvalued in 2026?
Based on GuruFocus' analysis, Radiopharm Theranostics stock appears to be undervalued.
The current stock price of $2.08 is trading 11.1% below its estimated GF Value™ of $2.34.
GuruFocus considers Radiopharm Theranostics to be Modestly Undervalued.
Key valuation signals for RADX:
Interest Coverage: 0 (At Loss)
GF Value™: $2.34 vs. price of $2.08 (11.1% below fair value)
No single metric tells the full story. See the RADX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
33GF Score
Get the complete analysis for RADX
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RADX has been successfully added to your 
